PURPOSE: To evaluate whether intravesical protrusion of the prostate (IPP) is related to the treatment effect of alpha-1 receptor antagonist in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) with a prostate size of less than 40 g.
METHODS: A total of 77 BPH patients over 50 years of age treated with alfuzosin (alpha blocker) were enrolled prospectively. The study included only patients with BPH of 40 g or less. The patients were classified into two groups depending on the presence of IPP at baseline: the IPP group (41 patients) and the non-IPP group (36 patients). Prostate volume, prostate-specific antigen (PSA), International Prostate Symptom Score and quality of life (IPSS/QoL), maximum flow rate (Qmax), and postvoid residual (PVR) volume were compared between the groups. The clinical significance of IPP was evaluated after the patients had been taking alfuzosin for 8 weeks.
RESULTS: PSA and IPSS (total and voiding subscore) showed significant correlations with IPP (P< 0.05). Comparison of parameters before and after 8 weeks showed that alfuzosin improved the total IPSS and all subscores (P< 0.001), QoL (P< 0.001), Qmax (P< 0.001), and PVR (P=0.030) in the non-IPP group.
CONCLUSIONS: Alfuzosin may be less effective in improving symptom scores, PVR, and Qmax in the treatment of LUTS/BPH in the presence of IPP.
Written by:
Seo YM, Kim HJ. Are you the author?
Department of Urology, Dankook University College of Medicine, Cheonan, Korea.
Reference: Int Neurourol J. 2012 Dec;16(4):187-90.
doi: 10.5213/inj.2012.16.4.187
PubMed Abstract
PMID: 23346485
